- Home
- DYN vs GOF Comparison
DYN vs GOF Comparison
Compare DYN & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- GOF
- Stock Information
- Founded
- DYN 1984
- GOF 2006
- Country
- DYN United States
- GOF United States
- Employees
- DYN N/A
- GOF N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- GOF Finance/Investors Services
- Sector
- DYN Health Care
- GOF Finance
- Exchange
- DYN Nasdaq
- GOF Nasdaq
- Market Cap
- DYN 2.6B
- GOF 2.5B
- IPO Year
- DYN 2020
- GOF N/A
- Fundamental
- Price
- DYN $9.23
- GOF $15.51
- Analyst Decision
- DYN Strong Buy
- GOF
- Analyst Count
- DYN 12
- GOF 0
- Target Price
- DYN $47.73
- GOF N/A
- AVG Volume (30 Days)
- DYN 1.8M
- GOF 789.2K
- Earning Date
- DYN 05-01-2025
- GOF 01-01-0001
- Dividend Yield
- DYN N/A
- GOF 15.42%
- EPS Growth
- DYN N/A
- GOF N/A
- EPS
- DYN N/A
- GOF N/A
- Revenue
- DYN N/A
- GOF N/A
- Revenue This Year
- DYN N/A
- GOF N/A
- Revenue Next Year
- DYN N/A
- GOF N/A
- P/E Ratio
- DYN N/A
- GOF N/A
- Revenue Growth
- DYN N/A
- GOF N/A
- 52 Week Low
- DYN $9.17
- GOF $10.96
- 52 Week High
- DYN $47.45
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- DYN 26.62
- GOF 41.99
- Support Level
- DYN $10.72
- GOF $15.38
- Resistance Level
- DYN $12.00
- GOF $15.93
- Average True Range (ATR)
- DYN 0.76
- GOF 0.15
- MACD
- DYN -0.11
- GOF -0.04
- Stochastic Oscillator
- DYN 1.52
- GOF 23.64
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.